Cancer Research The Future of Cancer Research: Science and Patient Impact
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 34, 1838-1842, August 1, 1974]
© 1974 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brox, L. W.
Right arrow Articles by Shannahoff, D. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brox, L. W.
Right arrow Articles by Shannahoff, D. H.

Studies on the Growth Inhibition and Metabolism of 2'-Deoxy-2'-fluorocytidine in Cultured Human Lymphoblasts1

L. W. Brox2, G. A. LePage, Sheldon S. Hendler and D. H. Shannahoff

McEachern Laboratory and Department of Biochemistry, University of Alberta, Edmonton, Alberta, T6G 2E1, Canada [L. W. B., G. A. L.], and Department of Biology, University of California, San Diego, California 92037 [S. S. H., D. H. S.]

The nucleoside 2'-deoxy-2'-fluorocytidine (FCdR) inhibits the growth of various human lymphoblastic cell lines in culture. FCdR is deaminated to 2'-deoxy-2'-fluorouridine and phosphorylated to the triphosphate level. Two additional FCdR-containing metabolites, comprising about 50% of the acid-soluble metabolites, were also detected. The FCdR incorporated into acid-insoluble material was primarily in DNA. Deoxycytidine protected these cell lines from growth inhibition by FCdR, but for only a limited time.

1 This work was supported by grants from the National Cancer Institute of Canada, by NIH Grant CA 12960, and by the University of California (Cancer Research Funds). Part of this work was done while Dr. S. S. Hendler and Dr. D. H. Shanahoff were at the Salk Institute, San Diego, Calif. 92112. An initial report was presented at the 162nd National Meeting, American Chemical Society, September 12 to 17, 1971.

2 To whom reprint requests should be addressed.

Received 1/ 8/74. Accepted 4/10/74.




This article has been cited by other articles:


Home page
Antimicrob. Agents Chemother.Home page
L. J. Stuyver, T. R. McBrayer, T. Whitaker, P. M. Tharnish, M. Ramesh, S. Lostia, L. Cartee, J. Shi, A. Hobbs, R. F. Schinazi, et al.
Inhibition of the Subgenomic Hepatitis C Virus Replicon in Huh-7 Cells by 2'-Deoxy-2'-Fluorocytidine
Antimicrob. Agents Chemother., February 1, 2004; 48(2): 651 - 654.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1974 by the American Association for Cancer Research.